Antiemetic Neurokinin-1 Receptor Blockers

Earn CME/CE in your profession:


Continuing Education Activity

Neurokinin-1 (NK-1) receptor antagonists are a class of antiemetic drugs that possess unique anxiolytic, antidepressant, and antiemetic properties. The discovery of neurokinin-1 (NK-1) receptor blockers was a crucial point in the prevention of emesis associated with cancer chemotherapy. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of antiemetic neurokinin-1 receptor blockers in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients who can benefit therapeutically from these agents.

Objectives:

  • Summarize the mechanism of action of neurokinin-1 (NK-1) receptor blockers.
  • Identify the approved indications for neurokinin-1 (NK-1) receptor blockers.
  • Review the adverse events and contraindications of neurokinin-1 (NK-1) receptor blockers.
  • Outline interprofessional team strategies for improving care coordination and communication to advance appropriate clinical outcomes with neurokinin-1 (NK-1) receptor blocker therapy to treat nausea and vomiting and drive the optimal outcomes.

Indications

Neurokinin-1 (NK-1) receptor antagonists are a class of antiemetic drugs that possess unique anxiolytic, antidepressant, and antiemetic properties. The discovery of neurokinin-1 (NK-1) receptor blockers was crucial in preventing emesis associated with cancer chemotherapy.[1][2]

The neurokinin-1 receptor inhibitor class is one of the seven classes of drugs used to suppress nausea and vomiting in patients associated with cancer chemotherapy. The classes of antiemetic drugs are serotonin (5-HT) receptor antagonists, dopamine (D) receptor antagonists, histamine (H) receptor antagonists, neurokinin-1 receptor (NK-1) antagonists, antimuscarinics, cannabinoids, and corticosteroids. Patients’ development of nausea, vomiting, and vertigo may be due to pregnancy, during cancer chemotherapy, and motion sickness in a car, boat, or ship cruise. Some examples of the neurokinin-1 receptor inhibitors are aprepitant, rolapitant, casopitant, netupitant, maropitant, and fosaprepitant. A new, highly selective NK-1 receptor antagonist, rolapitant, has an exceptionally long plasma half-life, T1/2 (180 hours), and it was FDA approved in September 2015 for the prevention of chemotherapy-induced delayed emesis.

Clinical Uses of Neurokinin-1 Receptor Antagonists

Neurokinin-1 receptor (NK-1) antagonists such as aprepitant, rolapitant, casopitant, fosaprepitant, netupitant, and maropitant are effective to treat postsurgical nausea and vomiting and cancer chemotherapy-induced nausea and vomiting. Fosaprepitant administration is via an intravenous (IV) formulation that is converted within 30 minutes to aprepitant after infusion. Aprepitant is available for administration orally or IV in multiple strengths. There is a combination of netupitant/palonosetron in an oral formulation. Casopitant is an investigational medication in development. Maropitant is an antiemetic for use in dogs and cats in the United States.

Off-Label Uses of Neurokinin-1 Receptor Antagonists

There are currently no off-label uses for neurokinin-1 receptor antagonists reported.

Mechanism of Action

NK-1 receptor antagonists have antinausea and anti-vomiting properties relayed through a central blockade in the area postrema, nucleus tractus solitarius, and visceral afferent nerves. NK-1 receptors mediate most of the central and peripheral effects of substance P. Substance P is an excitatory neurotransmitter that has a role in pain perception. It is among a class of neuropeptides called neurokinins. Its receptor, NK-1, is a G protein-coupled consisting of seven transmembrane helical elements. Therefore, NK-1 receptor antagonists can prevent both central and peripheral stimulation of vomiting centers. NK-1 receptor antagonists such as aprepitant (oral and IV formulations) are highly selective NK-1 receptor antagonists which cross the blood-brain barrier and occupy NK-1 receptors in the brain. Animal and human positron emission tomography (PET) studies with NK-1 receptor antagonists have shown that it crosses the blood-brain barrier and occupies brain NK-1 receptors. Aprepitant has no affinity for corticosteroid, serotonin, or dopamine receptors.[3][4]

Nausea and vomiting associated with emetogenic chemotherapy have two components: a universally acute phase experienced within 24 hours after chemotherapy and a delayed phase that affects only some patients on days 2 through 5. Serotonin (5-HT3) receptor antagonists are not very effective against delayed emesis. However, inhibitors of the NK-1 receptors, i.e., the receptors for the neuropeptide substance P, such as aprepitant (and its parenteral formulation fosaprepitant), have antiemetic effects preventing delayed nausea and improve the efficacy of standard antiemetic regimens in patients receiving multiple cycles of chemotherapy.[5][6]

Administration

Pharmacodynamics/Pharmacokinetics

In the fasted state, and after a single oral dose of 40 mg of aprepitant, the mean area under the plasma concentration-time curve (AUC0-∞) is found to be 7.8 mcg x hr/mL, and the mean peak plasma concentration (Cmax) is 0.7 mcg/mL, observed at approximately 3 hours after dose administration (Tmax).

After a single 125 mg oral dose of aprepitant on day 1 and 80 mg once daily on days 2 and 3, the area under the curve (AUC) for 0 to 24 hours is found to be 19.6 mcg x hr/mL and 21.2 mcg x hour/mL on day 1 and day 3, respectively. The Cmax of 1.6 mcg/mL and 1.4 mcg/mL were observed in approximately 4 hours (Tmax) on day 1 and day 3, respectively. Aprepitant pharmacokinetics is found to be non-linear across the clinical dose range. 

Route of Administration

Oral and IV for aprepitant, and IV for fosaprepitant.

The NK-1 receptor antagonist aprepitant is sometimes given with a 5-HT3 antagonist and a glucocorticoid, e.g., ondansetron and dexamethasone. Ralopitant and netupitant are oral formulations.[7]

Onset of Action

For oral aprepitant, the onset of action is 1 hour, the peak blood concentration is 4 hours as published in the manufacturer’s package insert.

Duration of Action

The duration of action of aprepitant is 24 hours as published in the manufacturer’s package insert and other publications. According to the pharmacokinetic principle, it should take approximately 4 to 5 half-lives (T1/2) to eliminate most of the absorbed drug from the body. Therefore, one should expect the duration of action of aprepitant to be at least 40 hours.

Distribution

The volume of distribution of aprepitant is 70 liters.

The mean absolute oral bioavailability of aprepitant is approximately 60% to 65%.[7]

Protein Binding

Protein binding for neurokinin-1 (NK-1) receptor antagonists, e.g., aprepitant, is greater than 95%.

Metabolism

NK-1 receptor antagonists, such as aprepitant, are metabolized primarily by cytochrome P450 enzymes, e.g., CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Researchers have identified seven less active metabolites of aprepitant in human plasma.[8]

Clearance

Apparent plasma clearance of aprepitant is 62 to 90 mL/min.[7]

Elimination Half-life

The biological half-life of aprepitant (neurokinin-1 (NK-1) receptor antagonist) is 9 to 13 hours. Aprepitant is eliminated primarily by metabolism through the liver; the kidneys do not excrete it.

Excretion

After a single administration of an intravenous 100 mg dose of radiolabeled [14C]-aprepitant in healthy subjects, 45% of the radioactivity was recoverable in feces and 57% in the urine. There was no study conducted with a radiolabeled capsule formulation. The results of excretion after oral and intravenous administration may differ.

Adverse Effects

Adverse Reactions: Severe

  • Hives and rash
  • Stevens-Johnson syndrome

Adverse Reactions: Mild

  • Sleepiness
  • Diarrhea
  • Weakness
  • Tiredness
  • Constipation
  • Gas
  • Stomach pain
  • Heartburn
  • Nausea
  • Hiccups
  • Loss of appetite
  • Headache
  • Fever
  • Itching
  • Hair loss

Pregnancy

Do not take neurokinin-1 (NK-1) receptor antagonists if pregnant or planning to get pregnant or breastfeeding. During treatment with neurokinin-1 (NK-1) receptor antagonists, if a patient is on birth control medication, the patient should use an additional method of birth control to avoid unplanned or unwanted pregnancy. Additionally, the patient should continue with other pregnancy protection for one month after treatment with neurokinin-1 (NK-1) receptor antagonists, e.g., aprepitant. It was FDA classified as pregnancy Class B under the prior system for pregnancy classification.[9]

Drug Interactions

Potential drug interactions can occur with neurokinin-1 (NK-1) receptor antagonists with concomitant medications because of changes in drug metabolism, e.g., CYP3A4 inhibition; this can occur in patients taking prescription and non-prescription medications, as well as herbal and nutritional supplements. The following is a list of potential drug interactions that may require drug monitoring or avoid combination: warfarin (monitor therapy); ivabradine (avoid combination); antifungals such as ketoconazole and itraconazole; lansoprazole; clarithromycin; diltiazem; carbamazepine; HIV protease inhibitors, such as ritonavir, and nelfinavir; hormonal contraceptives; nefazodone; oral steroids such as dexamethasone and methylprednisolone; paroxetine; phenytoin; cancer chemotherapy medications such as docetaxel, etoposide, ifosfamide, imatinib, irinotecan, paclitaxel, tamoxifen, vinblastine, vincristine, and vinorelbine; rifampin; tolbutamide; and troleandomycin; benzodiazepines such as alprazolam, diazepam, midazolam, and triazolam.[7][9]

Contraindications

Patients taking pimozide should not take neurokinin-1 (NK-1) receptor antagonists. Inhibition of CYP3A4 enzyme by neurokinin-1 (NK-1) receptor antagonists, e.g., aprepitant, could precipitate elevated plasma concentrations of pimozide, which is a CYP3A4 substrate. Drug interaction between pimozide and aprepitant could cause serious or life-threatening reactions, such as QTc prolongation, which is a known adverse reaction of pimozide. Neurokinin-1 (NK-1) receptor antagonists, e.g., aprepitant, is also contraindicated with the following drugs: 

  • Astemizole
  • Cisapride
  • Flibanserin
  • Lomitapide
  • Pimozide
  • Terfenadine
  • Ivabradine

Do not take neurokinin-1 (NK-1) receptor antagonists if pregnant or planning to get pregnant or breastfeeding. During treatment with neurokinin-1 (NK-1) receptor antagonist, if a patient is on birth control medication, the patient should use an additional method of birth control to avoid unplanned or unwanted pregnancy.[10] Additionally, the patient should continue with other pregnancy protection for one month after treatment with neurokinin-1 (NK-1) receptor antagonists, e.g., aprepitant. It was also FDA classified as Pregnancy Class B in the previous system.

Monitoring

There are no known monitoring requirements for neurokinin-1 (NK-1) receptor antagonists for the central nervous system, cardiovascular, respiratory, or other systems.

Toxicity

Symptoms of an overdose of neurokinin-1 (NK-1) receptor antagonists are drowsiness and headache. Aprepitant is associated with serum liver enzyme increases during therapy, but no verified correlation between cases of clinically specific liver injury with jaundice.

Serum aminotransferase elevations during aprepitant therapy occurred in 6% of treated patients versus 4.3% in controls receiving cancer chemotherapy. The aminotransferase elevations were found to be transient, were mild to moderate in severity in some cases, and may not be associated with symptoms or jaundice. There are no convincing published cases of clinically significant liver injury attributable to aprepitant in the literature. Therefore, significant liver injury from aprepitant or fosaprepitant would be exceeding rare.[8]

Enhancing Healthcare Team Outcomes

The neurokinin-1 receptor antagonists are very useful in managing nausea and vomiting from a variety of causes. Fosaprepitant is an intravenous (IV) formulation that converts within 30 minutes after infusion to aprepitant. Aprepitant is available as an oral or IV dosage form and this medication can be prescribed in two strengths. There is a combination of netupitant/palonosetron as an oral formulation. Casopitant is an investigational medication in development. While these drugs are safe and effective, they are prohibitively expensive and only used in hospital settings. Most hospital pharmacists are alerted when physicians order these drugs; the healthcare prescriber is then asked to prescribe something less expensive but just as effective.[11][12] To avoid increasing the cost of healthcare, a committee that includes a pharmacist, internist, nurse, and hospital administrator should develop practice guidelines on the use of these medications in hospitals.

Pharmacists, nurses, and physicians also need to be on the same page for therapeutic reasons. As mentioned above, there are significant drug interactions involved with neurokinin-1 receptor antagonists; pharmacists need to communicate with the ordering physician if any drug interactions can potentially alter the effectiveness of the patient's therapeutic regimen. Similarly, nursing must be aware and informed regarding the proper administration of the drug and can check with the pharmacist or the physician regarding any concerns. Nursing will also be in the best position to monitor treatment effectiveness and adverse reactions; the nurse should report any issues promptly to the treating physician. Neurokinin-1 receptor antagonists can be an important tool for oncologists, oncology-specialized nurses, and pharmacists to combat chemotherapy-related nausea. These examples highlight the need for an interprofessional team approach to neurokinin-1 receptor antagonist therapy to provide maximum therapeutic effect with minimal adverse events and drug interactions. [Level 5]


Article Details

Article Author

Michael Ibrahim

Article Editor:

Charles Preuss

Updated:

9/20/2021 7:34:50 AM

References

[1]

IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting. The Medical letter on drugs and therapeutics. 2018 Dec 3;     [PubMed PMID: 30653479]

[2]

Navari RM,Schwartzberg LS, Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets and therapy. 2018;     [PubMed PMID: 30323622]

[3]

Guan S,Zhang L,Zhong D,Ma Q,Meng F,Shao Y,Yu T,Liu X, [Curative Effect of Aprepitant Preventing CINV]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2018 Oct 20;     [PubMed PMID: 30309434]

[4]

Zhang Y,Hou X,Zhang R,Chen G,Huang Y,Yang Y,Zhao Y,Fang W,Hong S,Kang S,Zhou T,Zhang Z,Chen X,Zhang L, Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis. Future oncology (London, England). 2018 Aug;     [PubMed PMID: 30019968]

[5]

Gilmore J,D'Amato S,Griffith N,Schwartzberg L, Recent advances in antiemetics: new formulations of 5HT{sub}3{/sub}-receptor antagonists. Cancer management and research. 2018;     [PubMed PMID: 30013391]

[6]

Tsukiyama I,Hasegawa S,Ikeda Y,Takeuchi M,Tsukiyama S,Kurose Y,Ejiri M,Sakuma M,Saito H,Arakawa I,Inoue T,Yamaguchi E,Kubo A, Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer science. 2018 Sep;     [PubMed PMID: 29999572]

[7]

Jin Z,Daksla N,Gan TJ, Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting. Drugs. 2021 Jul     [PubMed PMID: 34106456]

[8]

Xiong J,Zhao G,Yang S,Chen J, Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. Advances in therapy. 2019 Feb     [PubMed PMID: 30607545]

[9]

Tan HS,Dewinter G,Habib AS, The next generation of antiemetics for the management of postoperative nausea and vomiting. Best practice & research. Clinical anaesthesiology. 2020 Dec     [PubMed PMID: 33288125]

[10]

Bailard N,Rebello E, Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. British journal of clinical pharmacology. 2018 Mar;     [PubMed PMID: 29266364]

[11]

Navari RM,Rapoport BL,Powers D,Arora S,Clark-Snow R, Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. Cancer medicine. 2018 May 23;     [PubMed PMID: 29790666]

[12]

Schwartzberg L, Getting it right the first time: recent progress in optimizing antiemetic usage. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018 Mar;     [PubMed PMID: 29556812]